On December 11, 2024, DOMA Perpetual Capital Management LLC announced that it intends to nominate 4 director candidates at the Company's 2025 annual meeting of stockholders and has hired Olshan Frome Wolosky LLP as counsel to represent it in its dealings with the Company. DOMA Perpetual stated that it believes strongly in the value of the Company's intellectual property and that the Company's stock is grossly undervalued. DOMA Perpetual urged the Company to immediately commence a stock tender offer for 10 million shares using its substantial cash on hand, and then execute its already-approved $150 million buyback program using the Company's healthy and growing free cash flow.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.44 USD | -4.11% |
|
-2.53% | +35.03% |
Jan. 31 | North American Morning Briefing : Investors in -2- | DJ |
Jan. 30 | Pacira BioSciences, Inc. Announces Board and Audit Committee Changes | CI |

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- DOMA Perpetual Capital Management Intends to Nominate Candidates at 2025 Annual Meeting of Pacira BioSciences